Home › Research › Treatments
Alzheimer-typical temporo-parietal atrophy and hypoperfusion are associated with a more significant cholinergic impairment in amnestic neurodegenerative syndromes
Nils Richter, Laura Breidenbach, Maximilian H.T. Schmieschek, Wolf‐Dieter Heiss, Gereon R. Fink, Özgür Onur. JuSER Publikationsportal, 2025-01-01
Topic: Brain proteins, microglia and lab models
However, postmortem investigations indicate that the AD-typical progressive amnestic syndrome may also result from predominantly limbic non-AD neuropathology such as TDP-43 proteinopathy and argyrophilic grain disease. A smaller Ch4p area of the BF was associated with a more significant ‘cholinergic deficit’, albeit to a lesser degree than cortical measures.ConclusionsIn clinically diagnosed AD, temporo-parietal GM and perfusion are more closely associated with the ‘cholinergic deficit’ than BF volumes, making them possible markers for cholinergic treatment response in amnestic neurodegeneration.IntroductionAlzheimer's disease (AD), biologically characterized by the accumulation of amyloid and tau pathologies and subsequent neurodegeneration,1 typically first presents with slowly progressive memory impairment. However, AD and non-AD (co)-pathologies are associated with specific hypometabolism and atrophy patterns:13,21–25 The common non-AD pathologies predominantly affect the medial temporal lobe, whereas AD also affects lateral temporal and parietal cortices.
Key findings
- However, postmortem investigations indicate that the AD-typical progressive amnestic syndrome may also result from predominantly limbic non-AD neuropathology such as TDP-43 proteinopathy and argyrophilic grain disease.
- A smaller Ch4p area of the BF was associated with a more significant ‘cholinergic deficit’, albeit to a lesser degree than cortical measures.ConclusionsIn clinically diagnosed AD, temporo-parietal GM and perfusion are more closely associated with the ‘cholinergic deficit’ than BF volumes, making them possible markers for cholinergic treatment response in amnestic neurodegeneration.IntroductionAlzheimer's disease (AD), biologically characterized by the accumulation of amyloid and tau pathologies and subsequent neurodegeneration,1 typically first presents with slowly progressive memory impairment.
- However, AD and non-AD (co)-pathologies are associated with specific hypometabolism and atrophy patterns:13,21–25 The common non-AD pathologies predominantly affect the medial temporal lobe, whereas AD also affects lateral temporal and parietal cortices.
Why it matters
In clinically diagnosed Alzheimer's disease, temporo-parietal gray matter and perfusion were more closely associated with cholinergic deficit than basal forebrain volumes, making them possible markers for cholinergic treatment response. The study also notes that the typical progressive amnestic syndrome may result from non-Alzheimer's limbic pathologies such as TDP-43 proteinopathy and argyrophilic grain disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record and senior author's track record, so those were left out: it earned 25 of the 92 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (JuSER Publikationsportal) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Özgür Onur holds only 3 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Forschungszentrum Jülich: institution h-index 672 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 25 / 92 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 25 of the 92 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Richter, N., Breidenbach, L., Schmieschek, M. H., Heiss, W., Fink, G. R., & Onur, Ö. (2025). Alzheimer-typical temporo-parietal atrophy and hypoperfusion are associated with a more significant cholinergic impairment in amnestic neurodegenerative syndromes. JuSER Publikationsportal. https://doi.org/10.34734/fzj-2025-01978
Vancouver
Richter N, Breidenbach L, Schmieschek MH, Heiss W, Fink GR, Onur Ö. Alzheimer-typical temporo-parietal atrophy and hypoperfusion are associated with a more significant cholinergic impairment in amnestic neurodegenerative syndromes. JuSER Publikationsportal. 2025. doi:10.34734/fzj-2025-01978.
BibTeX
@article{richter2025-e6dc4520,
author = {Richter, Nils and Breidenbach, Laura and Schmieschek, Maximilian H.T. and Heiss, Wolf‐Dieter and Fink, Gereon R. and Onur, Özgür},
title = {{Alzheimer-typical temporo-parietal atrophy and hypoperfusion are associated with a more significant cholinergic impairment in amnestic neurodegenerative syndromes}},
journal = {JuSER Publikationsportal},
year = {2025},
doi = {10.34734/fzj-2025-01978},
url = {https://doi.org/10.34734/fzj-2025-01978}
}
Related studies in Treatments
Also tagged “amyloid-beta”
1,339 studies in the library carry the topic tag “amyloid-beta”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,339 tagged studies.